CLINICAL TRIAL: ANTIRETROVIRAL ACTIVITY OF RALTEGRAVIR IN HIV-1 INFECTED CHILDRE

临床试验：雷特拉韦对 HIV-1 感染儿童的抗逆转录病毒活性

• 批准号: 8166839
• 负责人: STEPHEN A SPECTOR
• 金额: $ 0.04万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166839
• 关键词: Anti-Retroviral Agents; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dose; Drug Kinetics; Funding; Grant; HIV-1; Institution; Plasma; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objectives: 1. to evaluate the short term safety tolerability of raltegravir added to an initial stable background therapy in HIV-1 2. to evaluate the steady state plasma concentration profiles and pharmacokinetic parameters of raltgravir added to the stable background therapy 3. to evaluate the safety and tolerability of raltegravir at the selkected dose in combination with optimized background therapy

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 主要目标： 1。评估Raltegravir的短期安全耐受性，添加到HIV-1的初始稳定背景治疗中 2。评估Raltgravir的稳态血浆浓度谱和药代动力学参数添加到稳定的背景治疗中 3。评估Raltegravir在selked剂量上的安全性和耐受性与优化的背景治疗